SCHEMBL2385153

SCHEMBL2385153

O=C(Nc1cc(C(F)(F)F)cc(C(F)(F)F)c1)N1CCN(c2nsnc2OCc2ccnc(NCc3ccccc3)n2)CC1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 3/20 0.45
DGAT1 O75907 1/20 0.43
TRPV1 Q8NER1 4/20 0.41
HSD17B10 Q99714 2/20 0.40
NPSR1 Q6W5P4 1/20 0.40
PDGFRB P09619 1/20 0.40
LMNA P02545 2/20 0.40
HTT P42858 2/20 0.40
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
FAAH O00519 1/20 0.39
ALDH1A1 P00352 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
NR2E1 Q9Y466 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2383998 0.91 TRPV1 (0.43) MAPK10TRPV1HSD17B10NPSR1LMNA
SCHEMBL2383942 0.91 TRPV1 (0.44) MAPK10TRPV1HSD17B10NPSR1PDGFRB
SCHEMBL5573021 0.91 TRPV1 (0.44) MAPK10TRPV1HSD17B10NPSR1PDGFRB
SCHEMBL2381547 0.90 TRPV1 (0.43) MAPK10TRPV1HSD17B10NPSR1LMNA
SCHEMBL2384597 0.90 TRPV1 (0.42) MAPK10TRPV1HSD17B10NPSR1PDGFRB
SCHEMBL2382997 0.89 TRPV1 (0.44) MAPK10TRPV1HSD17B10NPSR1LMNA
SCHEMBL2384751 0.89 TRPV1 (0.43) MAPK10TRPV1HSD17B10NPSR1LMNA
SCHEMBL2384295 0.88 TRPV1 (0.42) MAPK10DGAT1TRPV1HSD17B10NPSR1
SCHEMBL12250948 0.88 TRPV1 (0.43) MAPK10TRPV1HSD17B10NPSR1LMNA
SCHEMBL12250932 0.88 TRPV1 (0.42) MAPK10TRPV1HSD17B10NPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US claimed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-8013156-B2 Tie-2 modulators and methods of use EXELIXIS, INC. (US) 2011-09-06 US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US disclosed
US-20070275952-A1 Tie-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275952-A1 Tie-2 Modulators and Methods of Use TIE1, TEK, KDR MAPK10 409/4885DGAT1 3041/4885TRPV1 4108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.